Publicaciones en colaboración con investigadores/as de University of Toronto (39)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  3. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma

    Cancer Epidemiology

  4. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

  5. Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses

    Frontiers in Cellular and Infection Microbiology, Vol. 13

2022

  1. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

2021

  1. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  2. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation

    Nature Genetics, Vol. 53, Núm. 9, pp. 1311-1321

  3. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  4. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

2019

  1. An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6709-6720

2018

  1. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients

    International Journal of Cancer, Vol. 142, Núm. 8, pp. 1594-1601

  2. Heterogeneity within the PF-EPN-B ependymoma subgroup

    Acta Neuropathologica, Vol. 136, Núm. 2, pp. 227-237

2017

  1. Neurochemical evidence supporting dopamine D1–D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation

    Brain Structure and Function, Vol. 222, Núm. 4, pp. 1767-1784

2016

  1. Disruption of a dopamine receptor complex amplifies the actions of cocaine

    European Neuropsychopharmacology, Vol. 26, Núm. 9, pp. 1366-1377

  2. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477

2015

  1. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma

    Cancer Discovery, Vol. 5, Núm. 9, pp. 920-931

  2. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  3. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

    Nature Medicine, Vol. 21, Núm. 6, pp. 555-559